Cetuximab Clinical Trials
81 recruitingDrug
Phase 145Phase 236Phase 314
Showing 1–20 of 81 trials
Recruiting
Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
Solid Tumor
Astellas Pharma Inc681 enrolled60 locationsNCT05382559
Recruiting
Phase 2Phase 3
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7+6 more
National Cancer Institute (NCI)613 enrolled342 locationsNCT01810913
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled177 locationsNCT06589804
Recruiting
Phase 1
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
Advanced/Metastatic Colorectal Adenocarcinoma
Bayer130 enrolled21 locationsNCT07535112
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Phase 3
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled191 locationsNCT04892173
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled250 locationsNCT06750094
Recruiting
Phase 1
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Advanced Malignant Tumors
Bristol-Myers Squibb437 enrolled8 locationsNCT06764771
Recruiting
Phase 2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Neoplasm Malignant
Merck Sharp & Dohme LLC150 enrolled62 locationsNCT07209111
Recruiting
Phase 1
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Colorectal, CancerPancreatic CancerNon-small Cell Lung Cancer+1 more
PAQ Therapeutics, Inc.210 enrolled9 locationsNCT07300150
Recruiting
Phase 2
SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT)
Rectal AdenocarcinomaHigh-Risk CancerMSS
Sixth Affiliated Hospital, Sun Yat-sen University49 enrolled1 locationNCT06908031
Recruiting
Phase 3
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
Rectal AdenocarcinomaHigh-Risk CancerMSS
Sixth Affiliated Hospital, Sun Yat-sen University204 enrolled1 locationNCT07549399
Recruiting
Phase 2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Solid Tumors
Mirati Therapeutics Inc.170 enrolled100 locationsNCT07415031
Recruiting
Phase 1Phase 2
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.210 enrolled2 locationsNCT07059221
Recruiting
Phase 2
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Malignant Neoplasm
Merck Sharp & Dohme LLC130 enrolled33 locationsNCT07252739
Recruiting
Phase 1Phase 2
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Metastatic Colorectal CancerKRAS G12C Mutations
M.D. Anderson Cancer Center31 enrolled2 locationsNCT06412198
Recruiting
Phase 2
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma
Locally Recurrent Oral Cavity Squamous Cell Carcinoma
M.D. Anderson Cancer Center17 enrolled1 locationNCT06448026
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled84 locationsNCT04929223
Recruiting
Phase 1Phase 2
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Solid Tumor
Sanofi542 enrolled22 locationsNCT05584670
Recruiting
Phase 1
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Colorectal, CancerNon-small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Eli Lilly and Company630 enrolled52 locationsNCT06586515